Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer [0.03%]
前列腺癌患者接受外照射、根治性前列腺切除术或近距离放疗后的长期(10年)胃肠道和泌尿生殖系统毒性反应
Grant K Hunter,Chandana A Reddy,Eric A Klein et al.
Grant K Hunter et al.
Objective.To examine gastrointestinal (GI) and genitourinary (GU) toxicity profiles of patients treated in 1999 with external beam radiotherapy (RT), prostate interstitial brachytherapy (PI) or radical prostatectomy (RP). Methods. TThe reco...
Postoperative radiotherapy after radical prostatectomy: indications and open questions [0.03%]
根治性前列腺切除术后的术后放疗：指征及未决问题
Pirus Ghadjar,Daniel Zwahlen,Daniel M Aebersold et al.
Pirus Ghadjar et al.
Biochemical relapse after radical prostatectomy occurs in approximately 15-40% of patients within 5 years. Postoperative radiotherapy is the only curative treatment for these patients. After radical prostatectomy, two different strategies c...
Teresa Maria Santos Amaral,Daniela Macedo,Isabel Fernandes et al.
Teresa Maria Santos Amaral et al.
Patients with castration-resistant prostate cancer (CRPC), who progress after docetaxel therapy, had until very recently, only a few therapeutic options. Recent advances in this field brought about new perspectives in the treatment of this ...
Histone deacetylase inhibitors restore cell surface expression of the coxsackie adenovirus receptor and enhance CMV promoter activity in castration-resistant prostate cancer cells [0.03%]
组蛋白去乙酰化酶抑制剂恢复细胞表面Coxsackie腺病毒受体的表达并增强CMV启动子在去势抵抗性前列腺癌细胞中的活性
Laura Kasman,Georgiana Onicescu,Christina Voelkel-Johnson
Laura Kasman
Adenoviral gene therapy using the death receptor ligand TRAIL as the therapeutic transgene can be safely administered via intraprostatic injection but has not been evaluated for efficacy in patients. Here we investigated the efficacy of ade...
Factors implicated in radiation therapy failure and radiosensitization of prostate cancer [0.03%]
影响放射治疗失败及前列腺癌放射增敏的因素
Helmut Bonkhoff
Helmut Bonkhoff
Tissue markers may be helpful in enhancing prediction of radiation therapy (RT) failure of prostate cancer (PCa). Among the various biomarkers tested in Phase III randomized trials conducted by the Radiation Therapy Oncology Group, p16, Ki-...
Racial disparities in prostate cancer incidence, biochemical recurrence, and mortality [0.03%]
前列腺癌发病、生化复发和死亡的种族差异
Cathryn H Bock,Isaac Powell,Rick A Kittles et al.
Cathryn H Bock et al.
Environment as a potential key determinant of the continued increase of prostate cancer incidence in martinique [0.03%]
环境可能是马提尼克地区前列腺癌发病率持续升高的潜在关键决定因素
Dominique Belpomme,Philippe Irigaray
Dominique Belpomme
Prostate cancer incidence is steadily increasing in many developed countries. Because insular populations present unique ethnic, geographical, and environmental characteristics, we analyzed the evolution of prostate cancer age-adjusted worl...
Costantine Albany,Ajjai S Alva,Ana M Aparicio et al.
Costantine Albany et al.
Prostate cancer (PC) is the most commonly diagnosed nonskin malignancy and the second most common cause of cancer death among men in the United States. Epigenetics is the study of heritable changes in gene expression caused by mechanisms ot...
Role of heparan sulfate 2-o-sulfotransferase in prostate cancer cell proliferation, invasion, and growth factor signaling [0.03%]
硫酸乙酰肝素2-O-磺基转移酶在前列腺癌细胞增殖、侵袭和生长因子信号传导中的作用
Brent W Ferguson,Sumana Datta
Brent W Ferguson
Heparan-sulfate proteoglycans (HSPGs) are required for maximal growth factor signaling in prostate cancer progression. The degree of sulfate modification on the covalently attached heparan sulfate (HS) chains is one of the determining facto...
A retrospective study on pathologic features and racial disparities in prostate cancer [0.03%]
一项关于前列腺癌病理特征和种族差异的回顾性研究
Steven A Bigler,Charles R Pound,Xinchun Zhou
Steven A Bigler
We reviewed more than 3,000 pathology reports on prostate cancer-related surgical specimens and analyzed racial disparities in histological and clinical features at the time of initial biopsy, diagnosis of prostate cancer, and prostatectomy...